Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

PURPOSE: To evaluate the maximum-tolerated dose (MTD), safety, and efficacy of elotuzumab in combination with bortezomib in patients with relapsed or relapsed and refractory multiple myeloma (MM). PATIENTS AND METHODS: Elotuzumab (2.5, 5.0, 10, or 20 mg/kg intravenously [IV]) and bortezomib (1.3 mg/...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Jakubowiak, Andrzej J., Benson, Don M., Bensinger, William, Siegel, David S.D., Zimmerman, Todd M., Mohrbacher, Ann, Richardson, Paul G., Afar, Daniel E.H., Singhal, Anil K., Anderson, Kenneth C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2012
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874204/
https://ncbi.nlm.nih.gov/pubmed/22291084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.7069
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky